Astrocyte Pharmaceuticals reports the completion of a Series A financing that raised $6.0M. Astrocyte is progressing its lead development candidate AST-004 to address the unmet need for a drug that can reduce injury to the brain resulting from stroke, traumatic brain injury (TBI), concussion, or other neurodegenerative conditions … more